143 related articles for article (PubMed ID: 9193367)
21. [Pathologic diagnosis and subtyping of lymphoma in bone marrow biopsies using histologic examination, immunohistochemistry and gene rearrangement studies].
Xiao JC; Jin XL; Yuan F
Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):120-4. PubMed ID: 15132847
[TBL] [Abstract][Full Text] [Related]
22. Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome.
Zoldan MC; Inghirami G; Masuda Y; Vandekerckhove F; Raphael B; Amorosi E; Hymes K; Frizzera G
Br J Haematol; 1996 May; 93(2):475-86. PubMed ID: 8639452
[TBL] [Abstract][Full Text] [Related]
23. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
24. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
25. [Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
Wang L; Wang W; Li X; Guo Y; Zhu X
Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):307-12. PubMed ID: 25030862
[TBL] [Abstract][Full Text] [Related]
26. [Typing of malignant mantle zone lymphomas].
Bednár B
Cesk Patol; 1996 May; 32(2):60-5. PubMed ID: 9560902
[TBL] [Abstract][Full Text] [Related]
27. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
28. Molecular diagnosis of mantle cell lymphoma in paraffin-embedded tissue.
Lasota J; Franssila K; Koo CH; Miettinen M
Mod Pathol; 1996 Apr; 9(4):361-6. PubMed ID: 8729972
[TBL] [Abstract][Full Text] [Related]
29. p27(Kip1) immunostaining for the differential diagnosis of small b-cell neoplasms in trephine bone marrow biopsies.
Kremer M; Dirnhofer S; Nickl A; Hoefler H; Quintanilla-Martínez L; Fend F
Mod Pathol; 2001 Oct; 14(10):1022-9. PubMed ID: 11598173
[TBL] [Abstract][Full Text] [Related]
30. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy.
Sarris AH; Braunschweig I; Medeiros LJ; Duvic M; Ha CS; Rodriguez MA; Hagemeister FB; McLaughlin P; Romaguera J; Cox J; Cabanillas F
J Clin Oncol; 2001 Jan; 19(2):398-405. PubMed ID: 11208831
[TBL] [Abstract][Full Text] [Related]
31. Morphonuclear comparison of the mantle zone and diffuse subtypes of mantle cell lymphoma.
Wojcik EM; Katz RL; Fanning TV; Johnston DA
Anal Quant Cytol Histol; 1994 Aug; 16(4):287-92. PubMed ID: 7524517
[TBL] [Abstract][Full Text] [Related]
32. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
Hausdorff J; Davis E; Long G; Hoppe R; van der Pas M; Lassman C; Kamel O; Jacobs C
Cancer J Sci Am; 1997; 3(5):303-11. PubMed ID: 9327155
[TBL] [Abstract][Full Text] [Related]
33. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
Coiffier B; Gisselbrecht C; Vose JM; Tilly H; Herbrecht R; Bosly A; Armitage JO
J Clin Oncol; 1991 Feb; 9(2):211-9. PubMed ID: 1703226
[TBL] [Abstract][Full Text] [Related]
35. Patterns of survival in mantle cell lymphoma.
Zucca E; Roggero E; Pinotti G; Pedrinis E; Cappella C; Venco A; Cavalli F
Ann Oncol; 1995 Mar; 6(3):257-62. PubMed ID: 7612491
[TBL] [Abstract][Full Text] [Related]
36. Non-Hodgkin's lymphomas of primary follicle/mantle zone origin.
Weisenburger DD
Leukemia; 1991; 5 Suppl 1():26-9. PubMed ID: 1716336
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Conlan MG; Bast M; Armitage JO; Weisenburger DD
J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
[TBL] [Abstract][Full Text] [Related]
38. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Al-Batran SE; Kim SZ; Welslau M; Hecker R; Kofahl-Krause D; Josten KM; Dürk H; Rost A; Neise M; von Grünhagen U; Chow KU; Hansmann ML; Hoelzer D; Mitrou PS
J Clin Oncol; 2005 May; 23(15):3383-9. PubMed ID: 15908650
[TBL] [Abstract][Full Text] [Related]
39. Conjunctival Lymphoma--An International Multicenter Retrospective Study.
Kirkegaard MM; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Toft PB; Vemuganti GK; Thuro BA; Curtin J; Heegaard S
JAMA Ophthalmol; 2016 Apr; 134(4):406-14. PubMed ID: 26891973
[TBL] [Abstract][Full Text] [Related]
40. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
